Publications by authors named "L Boublikova"
Background: Typically, the management of locally advanced rectal cancer consists of neoadjuvant chemoradiotherapy, followed by surgery and adjuvant chemotherapy. In addition to neoadjuvant chemoradiotherapy, total neoadjuvant therapy (TNT) involving radiotherapy and combined chemotherapy has been increasingly used and shown to reduce the risk of distant metastasis and improve local control. Patients with microsatellite instability and deficient mismatch repair (MSI/dMMR) tumors represent a specific group that benefits from different approaches if TNT is considered.
View Article and Find Full Text PDFArticle Synopsis
- Testicular cancer is the most common cancer in young men, with increasing rates and a high survival rate of 95%.
- Many patients show semen abnormalities before treatment, but the reasons behind these issues are not fully understood.
- This review will explore how mitochondrial dysfunction affects sperm quality by altering energy production pathways and increasing oxidative stress in testicular cancer patients.
Total neoadjuvant therapy in rectal cancer: the evidence and expectations.
Crit Rev Oncol Hematol
December 2023
Current management of locally advanced rectal cancer achieves high cure rates, distant metastatic spread being the main cause of patients' death. Total neoadjuvant therapy (TNT) employs (chemo)radiotherapy and combined chemotherapy prior to surgery to improve the treatment outcomes. TNT has been shown to reduce significantly distant metastases, increase disease-free survival by 5 - 10% in 3 years, and finally also overall survival (≈ 5% in 7 years).
View Article and Find Full Text PDFPurpose: Insomnia in cancer patients is a common symptom contributing to poor quality of life and poor functioning. Sleep disturbances have been associated with inflammatory activity, and systemic cancer therapies chemotherapy, hormonal therapy, and immunotherapy may cause insomnia. We have carried out a meta-analysis to estimate the occurrence of insomnia in patients with solid cancer treated with immunotherapy using checkpoint inhibitors (CPI).
View Article and Find Full Text PDFBackground: Testicular germ cell tumors (TGCT) are unique malignancies of young adult men; their biology is, however, underexplored and there has not been much progress in their treatment for decades. Circulating free tumor DNA (cfDNA) analysis represents a promising way of discovering novel diagnostic and treatment options.
Objective: The study evaluates the clinical value of cfDNA detection in TGCT patients.